Videos

Francesco Passamonti, MD, presents findings from a study on the combination of navitoclax and ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis at the 2022 ASH Annual Meeting & Exposition.

Ryan Jacobs, MD, discusses 5-year follow-up results from the CAPTIVATE study, which explored long-term outcomes after undetectable MRD with fixed-duration ibrutinib plus venetoclax in patients with CLL.

Riad Salem, MD, discusses data from 2 clinical trials comparing Y90 radioembolization vs conventional transarterial chemoembolization and drug-eluting bead transarterial chemoembolization for patients with HCC.

Anna Halpern, MD, presents study findings showing the addition of sorafenib to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone (CLAG-M) produces high rates of complete remission with MRD negativity in newly diagnosed AML and...

Leena Gandhi, MD, PhD, discusses the debate held at the 2022 Great Debates and Updates in Lung Cancer meeting, addressing first-line treatment options for patients with non-small cell lung cancer and PD-L1 > 50%.

Dr Mark Awad reviews his presentation at the 2022 Great Debates and Updates in Lung Cancer meeting in New York which focused on the management of patient resistance to checkpoint inhibitors.

Ryan Jacobs, MD, discusses findings from a real-world analysis exploring BTK inhibitor-class switching in the first-line treatment of CLL and SLL, suggesting approximately 40% of patients who switch from ibrutinib to acalabrutinib experience...

At the 2022 ASH Annual Meeting and Exposition, Abdulraheem Yacoub, MD, presented final results from a phase 2 study on the efficacy and safety of adding parsaclisib to ruxolitinib therapy in patients with myelofibrosis.

At the 2022 ASH Annual Meeting and Exposition in New Orleans, LA, Ajai Chari, MD, discusses talquetamab efficacy and safety for patients with heavily pretreated relapsed/refractory multiple myeloma.

At the 2022 San Antonio Breast Cancer Symposium, Aditya Bardia, MD, MPH, shared results from the phase 3 TROPiCS-02 trial investigating sacituzumab govitecan vs physician choice of chemotherapy in previously treated patients with HR+/HER2−...